NASH Core Curriculum: NASH Pathogenesis

Learn about the impact of NASH and the interplay with diabetes, obesity, and cardiovascular disease.
Brent A. Neuschwander-Tetri, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.03 MB
Released: February 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Supported by educational grants from
Gilead Sciences
Novo Nordisk Inc.

Related Content

Expert commentary discussing the complex interplay among NASH, obesity, and diabetes from Clinical Care Options (CCO)

Brent A. Neuschwander-Tetri, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 29, 2021 Expired: January 28, 2022

Kenneth Cusi, MD, FACP, FACE, and Stephen A. Harrison, MD, COL (Ret.), FAASLD, explain how to interpret endpoints used in NASH studies so you can evaluate emerging treatments

Kenneth Cusi, MD, FACP, FACE
Program Director
Stephen A. Harrison, MD, COL (Ret.), FAASLD
Released: March 26, 2019

Raymond E. Soccio, MD, PhD, summarizes the roles of weight loss and diabetes drugs in NASH

Raymond E. Soccio, MD, PhD Released: March 7, 2019

Philip N. Newsome, PhD, FRCPE, summarizes the roles of weight loss and diabetes drugs in NASH

Philip N. Newsome, PhD, FRCPE Released: March 6, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue